Welcome to our latest blog post on Focal Nodular Hyperplasia! As a medical professional, you may have encountered patients who have been diagnosed with this condition. It is important to understand what Focal Nodular Hyperplasia is and the available treatment options for your patients. In this article, we'll explore everything you need to know about Focal Nodular Hyperplasia - from its definition and types, to possible treatments and prognosis. So sit back, grab a cup of coffee, and let's dive in!
Focal Nodular Hyperplasia (FNH) is a benign liver tumor that occurs in both men and women. It typically forms from overgrowth of normal cells in the liver, resulting in an abnormal mass or nodule. FNH usually appears as a single nodule, although it can sometimes present with multiple nodules.
The exact cause of FNH is unknown, but there are several risk factors associated with this condition. These include oral contraceptive use, pregnancy, obesity, and liver trauma. However, many people who develop FNH do not have any identifiable risk factors.
Symptoms of Focal Nodular Hyperplasia are rare and often go unnoticed due to their non-specific nature. In some cases, patients may experience abdominal pain or discomfort or notice a palpable lump on the right side of their abdomen during physical examination.
Focal nodular hyperplasia (FNH) is a benign liver tumor. It can be divided into two main types based on its characteristics: classical FNH and non-classical FNH.
Classical FNH accounts for about 80% of all cases. This type of tumor has a well-defined central scar that can be seen on imaging tests such as CT or MRI scans. The central scar consists of fibrous tissue and blood vessels, which give it the typical "stellate" appearance.
When it comes to treating Focal Nodular Hyperplasia (FNH), there are several options available. However, the treatment approach will depend on factors such as the size and location of the nodules, symptoms present, and overall health of the patient.
In cases where FNH is small and not causing any symptoms or complications, no treatment may be necessary. Instead, regular monitoring through imaging tests may be recommended to ensure that the nodules do not grow or change over time.
For larger nodules or those causing discomfort or other symptoms, surgical removal may be considered. This can typically be done using minimally invasive techniques such as laparoscopy.
Focal Nodular Hyperplasia is a benign tumor that occurs in the liver. Although it can cause discomfort and anxiety for patients who are diagnosed with it, it has a great prognosis because of its non-cancerous nature. It's essential to know that most of these tumors don't need treatment at all and will disappear on their own.
However, if the patient needs treatment due to symptoms or other reasons, several options are available. These include surgery, embolization therapy, or medications.
Medical professionals should understand the different types of focal nodular hyperplasia and have full knowledge about each treatment option before recommending any course of action.
1.
Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.
2.
Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.
3.
Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap
4.
Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma
5.
Potential new therapy for childhood brain cancer could heal treatment-resistant tumors
1.
What is Hemorrhagic Cystitis and How to Manage its Symptoms
2.
How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?
3.
Blood Donation Sustainability Through Behavioral Science
4.
Emerging Therapies and Technologies Reshaping Oncology: Innovations and Impact in 2025
5.
Essential Developments in Oncology for Healthcare Excellence
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation